XTRA:NXU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Nexus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NXU's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.3%

NXU

11.4%

DE Healthcare Services

2.8%

DE Market


1 Year Return

21.2%

NXU

6.4%

DE Healthcare Services

0.3%

DE Market

Return vs Industry: NXU exceeded the German Healthcare Services industry which returned 6.4% over the past year.

Return vs Market: NXU exceeded the German Market which returned 0.3% over the past year.


Shareholder returns

NXUIndustryMarket
7 Day0.3%11.4%2.8%
30 Day6.8%3.1%0.5%
90 Day41.1%18.3%27.7%
1 Year21.2%21.2%7.0%6.4%2.3%0.3%
3 Year48.9%47.0%45.5%42.0%3.5%-4.9%
5 Year146.0%139.4%122.8%113.6%11.4%-3.4%

Price Volatility Vs. Market

How volatile is Nexus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nexus undervalued compared to its fair value and its price relative to the market?

2.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NXU (€39.5) is trading below our estimate of fair value (€40.64)

Significantly Below Fair Value: NXU is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: NXU is poor value based on its PE Ratio (56.8x) compared to the Healthcare Services industry average (15.9x).

PE vs Market: NXU is poor value based on its PE Ratio (56.8x) compared to the German market (20.5x).


Price to Earnings Growth Ratio

PEG Ratio: NXU is poor value based on its PEG Ratio (2.4x)


Price to Book Ratio

PB vs Industry: NXU is overvalued based on its PB Ratio (5.5x) compared to the DE Healthcare Services industry average (3.7x).


Next Steps

Future Growth

How is Nexus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

23.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXU's forecast earnings growth (23.2% per year) is above the savings rate (0.2%).

Earnings vs Market: NXU's earnings (23.2% per year) are forecast to grow faster than the German market (22.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NXU's revenue (6.1% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: NXU's revenue (6.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NXU's Return on Equity is forecast to be low in 3 years time (12%).


Next Steps

Past Performance

How has Nexus performed over the past 5 years?

7.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NXU has high quality earnings.

Growing Profit Margin: NXU's current net profit margins (7.1%) are lower than last year (7.7%).


Past Earnings Growth Analysis

Earnings Trend: NXU's earnings have grown by 7% per year over the past 5 years.

Accelerating Growth: NXU's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: NXU had negative earnings growth (-1.5%) over the past year, making it difficult to compare to the Healthcare Services industry average (-1.5%).


Return on Equity

High ROE: NXU's Return on Equity (10.5%) is considered low.


Next Steps

Financial Health

How is Nexus's financial position?


Financial Position Analysis

Short Term Liabilities: NXU's short term assets (€94.7M) exceed its short term liabilities (€68.9M).

Long Term Liabilities: NXU's short term assets (€94.7M) exceed its long term liabilities (€45.9M).


Debt to Equity History and Analysis

Debt Level: NXU is debt free.

Reducing Debt: NXU has no debt compared to 5 years ago when its debt to equity ratio was 5.3%.

Debt Coverage: NXU has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NXU has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Nexus's current dividend yield, its reliability and sustainability?

0.46%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: NXU's dividend (0.46%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).

High Dividend: NXU's dividend (0.46%) is low compared to the top 25% of dividend payers in the German market (3.83%).


Stability and Growth of Payments

Stable Dividend: NXU is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: NXU is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: NXU is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NXU's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average board tenure


CEO

Ingo Behrendt

no data

Tenure

€1,146,000

Compensation

Dr. Ingo Behrendt, MBA serves as the Chairman of the Executive Board and Chief Executive Officer at Nexus AG. 


CEO Compensation Analysis

Compensation vs Market: Ingo's total compensation ($USD1.29M) is about average for companies of similar size in the German market ($USD1.43M).

Compensation vs Earnings: Ingo's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Members

NamePositionTenureCompensationOwnership
Felicia Rosenthal
Member of the Supervisory Board5.17yrsno datano data
Juergen Rottler
Member of the Supervisory Board1.17yrsno datano data
Alexander Pocsay
Member of the Supervisory Board14.08yrsno datano data
Ulrich Krystek
Deputy Chairman of the Supervisory Board8.17yrsno datano data
Hans-Joachim Konig
Chairman of the Supervisory Boardno datano datano data
Dietmar Jena
Member of Supervisory Board1.17yrsno datano data
Jan Lühmann
Substitute Supervisory Board Memberno datano datano data
Cornelia Boesch
Substitute Supervisory Board Memberno datano datano data

5.2yrs

Average Tenure

Experienced Board: NXU's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nexus AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nexus AG
  • Ticker: NXU
  • Exchange: XTRA
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: €622.084m
  • Shares outstanding: 15.75m
  • Website: https://de-de.nexus-ag.de

Number of Employees


Location

  • Nexus AG
  • Irmastrasse 1
  • Donaueschingen
  • Baden-Württemberg
  • 78166
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXUDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2000
NXUXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJul 2000
0FGLLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2000
NXUSWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFJul 2000
NXUdBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2000

Biography

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a Web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 21:03
End of Day Share Price2020/07/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.